Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
71% of Adult Patients in Phase 2 ZUMA-3 Study Achieved a Complete Response Following a Single Infusion of Tecartus - If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Kite, a Gilead Company announced today results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, .
Trodelvy More than Doubled Overall Survival as Second-Line Treatment in New ASCENT Subgroup Analysis – Gilead Sciences, Inc. today announced new data from the Phase 3 ASCENT study evaluating Trodelvy ® in relapsed or refractory metastatic triple-negative breast cancer . In this subgroup analysis of brain metastases-negative patients who received only one line of prior systemic therapy in the metastatic setting in .
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021
Gilead Sciences, Inc. and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate as well as Kite’s chimeric antigen receptor T-cell … Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021. The abstracts, including two oral presentations, expand on the clinical profiles of Gilead’s antibody-drug conjugate (ADC), as well as Kite’s chimeric antigen receptor (CAR) T-cell therapies across a range of cance
The Small Business Administration announced hard-hit local restaurants and bars can apply for a share of $26 billion in COVID-19 relief beginning next Monday.